عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

For 1st Time in Saudi Arabia, Facility for Prosthetics Using 3D Technology

The use of the digital industry in the manufacture of limbs reduces the chance of human errors (Asharq Al-Awsat)
The use of the digital industry in the manufacture of limbs reduces the chance of human errors (Asharq Al-Awsat)
TT
TT

For 1st Time in Saudi Arabia, Facility for Prosthetics Using 3D Technology

The use of the digital industry in the manufacture of limbs reduces the chance of human errors (Asharq Al-Awsat)
The use of the digital industry in the manufacture of limbs reduces the chance of human errors (Asharq Al-Awsat)

Heal-Tec, a Saudi-based medical rehabilitation manufacturing facility, is the first of its kind in Saudi Arabia to manufacture prostheses, prosthetic devices and aids using digital industry that includes scanning and 3D printing.

Co-founded in 2020 by Dr. Hashim AlZain and Eng. Ayman Noori, HealTec is a dedicated B2B healthcare rehabilitation manufacturing facility that enables the local production of medical prosthetics and other devices to serve long-term care and rehabilitation patients.

In remarks to Asharq Al-Awsat, AlZain said that the use of digital industry in the manufacture of prosthetics has many benefits, including accuracy of measurements and speed of response, as it allows the production of accurate and complex parts more and faster than traditional methods, allowing patients to have a quick treatment and recovery.

According to AlZain, previous traditional methods were done either by using gypsum or meter measurements, and depended on the skill of the service provider; thus, human errors were frequent. But the use of this technology has greatly reduced these risks, he underlined.

AlZain noted that the size of the prosthetics market amounted to 3.7 billion Saudi riyals annually. He added that during the next five years, the factory’s share would reach 85 million riyals, to cover approximately 40 percent of the local needs.

Service providers in hospitals and rehabilitation centers usually import all the material from outside the Kingdom, which necessitates a long period of supply. Prosthetics and auxiliary devices may take more than three weeks to be supplied, which causes a backlog in appointments.

HealTec provides its manufacturing services to rehabilitation hospitals and healthcare centers across the Kingdom in record time compared to the traditional means, which rely heavily on imports.

The factory is also able to export prosthetics, devices, and aids to neighboring countries through the King Salman Humanitarian Aid and Relief Center, which enhances the implementation of the Kingdom’s Vision 2030.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”